Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Target Price from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have received an average recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $23.80.

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in Lexeo Therapeutics by 107.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after purchasing an additional 33,013 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. MetLife Investment Management LLC increased its position in Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after acquiring an additional 7,803 shares during the period. Vestal Point Capital LP raised its stake in Lexeo Therapeutics by 1.2% during the 3rd quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Verition Fund Management LLC lifted its position in Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after acquiring an additional 355,928 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $3.07 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $7.12. The firm has a market capitalization of $101.51 million, a price-to-earnings ratio of -0.97 and a beta of 3.85. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.